Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADMA BIOLOGICS, INC.ADMA · Entity 4477 | Director | May 27, 2026 | May 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADMA BIOLOGICS, INC.
Report date May 27, 2026 · Filed May 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 520,284 |
Reported balance
After 2026-05-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-27 · Purchase · Acquired 6,400 · Balance 520,284 F1: Represents an open market purchase in a single transaction. F2: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, half of which will vest on August 9, 2026, and the other half of which will vest on February 9, 2027, subject to the Reporting Person's continued service as of each such vesting date; and (ii) 509,594 shares of common stock owned by the Reporting Person. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 22,857 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 22,857 F3: These shares are owned by Brookwood LLC ("Brookwood"). The Reporting Person is the managing member of Brookwood. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 31,381 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 31,381 F4: These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 38,294 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 38,294 F5: These shares are owned by Genesis Foundation Inc. ("Genesis"). The Reporting Person is the President of Genesis. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 175 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 175 F6: These shares are owned by the Reporting Person's wife. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an open market purchase in a single transaction.
F2: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, half of which will vest on August 9, 2026, and the other half of which will vest on February 9, 2027, subject to the Reporting Person's continued service as of each such vesting date; and (ii) 509,594 shares of common stock owned by the Reporting Person.
F3: These shares are owned by Brookwood LLC ("Brookwood"). The Reporting Person is the managing member of Brookwood.
F4: These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee.
F5: These shares are owned by Genesis Foundation Inc. ("Genesis"). The Reporting Person is the President of Genesis.
F6: These shares are owned by the Reporting Person's wife.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 28, 2026 20:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 6,400 | $7.91 | $50,624.00 |
DisclosureSEC source: 0001140361-26-023127 · form4.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 520,284 F1 · balance_after: Represents an open market purchase in a single transaction. F2 · balance_after: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, half of which will vest on August 9, 2026, and the other half of which will vest on February 9, 2027, subject to the Reporting Person's continued service as of each such vesting date; and (ii) 509,594 shares of common stock owned by the Reporting Person. Read SEC document |
| May 12, 2026 Filed May 14, 2026 11:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 12,500 | $8.01 | $100,125.00 |
DisclosureSEC source: 0001140361-26-021150 · form4.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 513,884 F1 · balance_after: Represents an open market purchase in a single transaction. F2 · balance_after: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, half of which will vest on August 9, 2026, and the other half of which will vest on February 9, 2027, subject to the Reporting Person's continued service as of each such vesting date; and (ii) 503,194 shares of common stock owned by the Reporting Person. Read SEC document |
| May 11, 2026 Filed May 12, 2026 21:22 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 12,500 | $8.01 | $100,125.00 |
DisclosureSEC source: 0001140361-26-020855 · form4.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 501,384 F1 · balance_after: Represents an open market purchase in a single transaction. F2 · balance_after: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; and (ii) 490,694 shares of common stock owned by the reporting person. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (Right to Buy) · Derivative | 17,730 | $0.00 Strike: $16.37 | $0.00 |
DisclosureSEC source: 0001140361-26-004892 · form4.xml · derivative · entry 6 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,730 Underlying: Common Stock · 17,730 shares Expires 2036-02-09 F7 · derivative.exercise_date: These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 10,690 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-004892 · form4.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 488,884 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 472,749 shares of common stock owned by the reporting person. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001140361-25-022113 · form4.xml · derivative · entry 7 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: These options were granted on February 14, 2017 and vested in twenty-four equal monthly installments, becoming fully vested on February 14, 2019. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | SaleCommon Stock | 10,000 | $21.31 | $213,100.00 |
DisclosureSEC source: 0001140361-25-022113 · form4.xml · nonDerivative · entry 2 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 478,194 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.29 to $21.35. The reporting person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes, as of the transaction date, (i) 10,889 restricted stock units granted on February 19, 2025, which will vest in full on February 19, 2026, subject to the Reporting Person's continued service as of the applicable vesting date; and (ii) 467,305 shares of common stock owned by the reporting person. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 01:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 10,000 | $5.00 | $50,000.00 |
DisclosureSEC source: 0001140361-25-022113 · form4.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 488,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2025 Filed Feb 22, 2025 02:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (Right to Buy) · Derivative | 16,279 | $0.00 Strike: $16.07 | $0.00 |
DisclosureSEC source: 0001140361-25-005538 · form4.xml · derivative · entry 6 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,279 Underlying: Common Stock · 16,279 shares Expires 2035-02-19 F7 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| February 19, 2025 Filed Feb 22, 2025 02:05 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 10,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-005538 · form4.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 478,194 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, (i) 10,889 RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 12,020 restricted stock units granted on February 26, 2024, which will vest in full on February 26, 2025, subject to the Reporting Person's continued service as of the applicable vesting date; and (iii) 455,285 shares of common stock owned by the Reporting Person. Read SEC document |
| August 29, 2024 Filed Aug 31, 2024 01:02 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock · Derivative | 9,000 | $10.80 Strike: $10.80 | $97,200.00 |
DisclosureSEC source: 0001140361-24-039821 · form4.xml · derivative · entry 11 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2025-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · shares: The Reporting Person is exercising these options due, in part, to their near-term expiration date. F9 · derivative.exercise_date: These options were granted on January 30, 2015 and vested in twenty-four equal monthly installments, becoming fully vested on January 30, 2017. Read SEC document |
| August 29, 2024 Filed Aug 31, 2024 01:02 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock · Derivative | 9,000 | $5.96 Strike: $5.96 | $53,640.00 |
DisclosureSEC source: 0001140361-24-039821 · form4.xml · derivative · entry 10 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2026-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · shares: The Reporting Person is exercising these options due, in part, to their near-term expiration date. F8 · derivative.exercise_date: These options were granted on January 28, 2016 and vested in twenty-four equal monthly installments, becoming fully vested on January 28, 2018. Read SEC document |
| August 29, 2024 Filed Aug 31, 2024 01:02 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock · Derivative | 118,861 | $3.66 Strike: $3.66 | $435,031.26 |
DisclosureSEC source: 0001140361-24-039821 · form4.xml · derivative · entry 9 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 118,861 shares Expires 2027-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: These options were granted on June 6, 2017 and vested in twenty-four equal monthly installments, becoming fully vested on June 6, 2019. Read SEC document |
| August 29, 2024 Filed Aug 31, 2024 01:02 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | SaleCommon Stock | 136,861 | $17.27 | $2,363,931.62 |
DisclosureSEC source: 0001140361-24-039821 · form4.xml · nonDerivative · entry 4 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 467,305 F1 · price: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $17.17 to $17.595. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes, as of the transaction date, (i) 12,020 restricted stock units granted on February 26, 2024, which will vest in full on February 26, 2025, subject to the Reporting Person's continued service as of the applicable vesting date; and (ii) 455,285 shares of common stock owned by the reporting person. Read SEC document |
| August 29, 2024 Filed Aug 31, 2024 01:02 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 9,000 | $10.80 | $97,200.00 |
DisclosureSEC source: 0001140361-24-039821 · form4.xml · nonDerivative · entry 3 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 604,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2024 Filed Aug 31, 2024 01:02 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 9,000 | $5.96 | $53,640.00 |
DisclosureSEC source: 0001140361-24-039821 · form4.xml · nonDerivative · entry 2 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 595,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2024 Filed Aug 31, 2024 01:02 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 118,861 | $3.66 | $435,031.26 |
DisclosureSEC source: 0001140361-24-039821 · form4.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 586,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 37,541 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0001140361-24-010241 · form4.xml · derivative · entry 6 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,541 Underlying: Common Stock · 37,541 shares Expires 2034-02-26 F7 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 24,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-010241 · form4.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 467,305 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, (i) 24,040 RSUs granted on February 26, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 25,815 RSUs granted on March 6, 2023, which will vest in full on March 6, 2024; and (iii) 417,450 shares of common stock owned by the reporting person. Read SEC document |
| August 30, 2023 Filed Aug 30, 2023 20:58 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 130,000 | $3.71 | $482,144.00 |
DisclosureSEC source: 0001140361-23-041848 · form4.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 443,265 F1 · price: Reflects the weighted average price of purchases on August 30, 2023. The shares were purchased in multiple transactions ranging from $3.70 to $3.71, inclusive. F2 · balance_after: Includes, as of the transaction date, (i) 25,815 RSUs granted on March 6, 2023 that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date; and (ii) 417,450 shares of common stock owned by the reporting person. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 02:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 51,630 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001140361-23-010772 · form4.xml · derivative · entry 6 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,630 Underlying: Common Stock · 51,630 shares Expires 2033-03-06 F7 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 02:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 25,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-010772 · form4.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,265 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, (i) 25,815 RSUs granted on March 6, 2023 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 13,293 RSUs granted on March 7, 2022, which will vest in full on March 7, 2023; and (iii) 274,157 shares of common stock owned by the reporting person. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 22:58 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 53,172 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001140361-22-008670 · form4.xml · derivative · entry 6 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,172 Underlying: Common Stock · 53,172 shares Expires 2032-03-07 F7 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 22:58 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 26,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-008670 · form4.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,450 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date. F2 · balance_after: Includes (i) 26,586 RSUs granted on March 7, 2022 and reported on this Form 4, subject to vesting as set forth in footnote (1); and (ii) 260,864 shares of common stock owned by the reporting person. Read SEC document |
| October 25, 2021 Filed Oct 26, 2021 11:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 100,000 | $1.00 | $100,000.00 |
DisclosureSEC source: 0001140361-21-035381 · form4.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,864 F1 · shares: Represents a purchase from the underwriters in the October 2021 public offering of the issuer. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:03 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001193805-21-000295 · e620330_4-jgrossman.xml · derivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: The options vest in twelve equal monthly installments, becoming fully vested on February 25, 2022. Read SEC document |
| September 10, 2020 Filed Sep 11, 2020 12:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 5,000 | $2.22 | $11,100.00 |
DisclosureSEC source: 0001193805-20-001135 · e619926_4-jgrossman.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,864 F1 · balance_after: Includes 3,750 RSUs granted on February 28, 2020 which remain unvested as of the date hereof and will become fully vested on February 28, 2021, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 12:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 300 | $2.62 | $786.00 |
DisclosureSEC source: 0001193805-20-001069 · e619888_4-jgrossman.xml · nonDerivative · entry 2 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,864 F1 · balance_after: Includes 7,500 RSUs granted on February 28, 2020, which will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 12:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 5,000 | $2.56 | $12,800.00 |
DisclosureSEC source: 0001193805-20-001069 · e619888_4-jgrossman.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,564 F1 · balance_after: Includes 7,500 RSUs granted on February 28, 2020, which will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. Read SEC document |
| August 12, 2020 Filed Aug 13, 2020 12:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 5,000 | $2.90 | $14,475.00 |
DisclosureSEC source: 0001193805-20-001023 · e619872_4-jgrossman.xml · nonDerivative · entry 3 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,564 F1 · balance_after: Includes 7,500 RSUs granted on February 28, 2020, which will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. Read SEC document |
| August 12, 2020 Filed Aug 13, 2020 12:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 5,000 | $2.89 | $14,450.00 |
DisclosureSEC source: 0001193805-20-001023 · e619872_4-jgrossman.xml · nonDerivative · entry 2 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,564 F1 · balance_after: Includes 7,500 RSUs granted on February 28, 2020, which will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. Read SEC document |
| August 12, 2020 Filed Aug 13, 2020 12:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 200 | $2.87 | $574.00 |
DisclosureSEC source: 0001193805-20-001023 · e619872_4-jgrossman.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,564 F1 · balance_after: Includes 7,500 RSUs granted on February 28, 2020, which will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. Read SEC document |
| February 28, 2020 Filed Mar 4, 2020 00:09 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001193805-20-000288 · e619422_4-jgrossman.xml · derivative · entry 6 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-02-28 F7 · derivative.exercise_date: The option vests in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Mar 4, 2020 00:09 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-20-000288 · e619422_4-jgrossman.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,364 F1 · shares: These shares represent restricted stock units ("RSUs"), which will vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. F2 · balance_after: Includes (i) 7,500 RSUs granted on February 28, 2020 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; and (ii) 132,864 shares of common stock owned by the reporting person. Read SEC document |
| February 28, 2020 Filed May 1, 2020 21:12 UTC Amendment | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-20-000552 · e619598_4a-jgrossman.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,364 F1 · shares: These shares represent restricted stock units ("RSUs"). Subsequent to the filing of the initial Form 4 by the Reporting Person on March 3, 2020, the Board of Directors of the Issuer corrected the vesting schedule of the RSUs. The RSUs will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. F2 · balance_after: Includes (i) 7,500 RSUs granted on February 28, 2020 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; and (ii) 132,864 shares of common stock owned by the reporting person. Read SEC document |
| February 11, 2020 Filed Feb 11, 2020 15:15 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 22,857 | $3.50 | $79,999.50 |
DisclosureSEC source: 0001193805-20-000131 · e619334_4-jgrossman.xml · nonDerivative · entry 2 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,857 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. F2 · ownership.nature: These shares are owned by Brookwood LLC ("Brookwood"). The reporting person is the managing member of Brookwood. Read SEC document |
| February 11, 2020 Filed Feb 11, 2020 15:15 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 22,857 | $3.50 | $79,999.50 |
DisclosureSEC source: 0001193805-20-000131 · e619334_4-jgrossman.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,864 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. Read SEC document |
| May 17, 2019 Filed May 21, 2019 11:14 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 12,000 | $4.00 | $48,000.00 |
DisclosureSEC source: 0001193805-19-000524 · e618483_4-jgrossman.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,007 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.89 | $0.00 |
DisclosureSEC source: 0001193805-19-000295 · e618304_4-jgrossman.xml · derivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-03-13 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) March 13, 2029 and (ii) the one-year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| June 22, 2018 Filed Jun 25, 2018 21:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001193805-18-000901 · e618126_4-jgrossman.xml · derivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2028-06-22 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) June 22, 2028 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 11:10 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 31,381 | $4.78 | $150,001.18 |
DisclosureSEC source: 0001193805-18-000821 · e618087_4-jgrossman.xml · nonDerivative · entry 2 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 31,381 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. F2 · ownership.nature: These shares are owned by the Jerrold Grossman 2012 Nevada SLAT, of which Dr. Grossman serves as investment trustee. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 11:10 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | PurchaseCommon Stock | 20,921 | $4.78 | $100,002.38 |
DisclosureSEC source: 0001193805-18-000821 · e618087_4-jgrossman.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,007 F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering. Read SEC document |
| July 13, 2017 Filed Jul 17, 2017 21:13 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 48,185 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001193805-17-001299 · e616385_4-jgrossman.xml · derivative · entry 5 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,185 shares Expires 2017-07-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vested in equal monthly installments over the four (4) year period following July 16, 2007. Read SEC document |
| July 13, 2017 Filed Jul 17, 2017 21:13 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Tax withholdingCommon Stock | 39,132 | $3.30 | $129,135.60 |
DisclosureSEC source: 0001193805-17-001299 · e616385_4-jgrossman.xml · nonDerivative · entry 2 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,086 Read SEC document |
| July 13, 2017 Filed Jul 17, 2017 21:13 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | Exercise / conversionCommon Stock | 48,185 | $2.68 | $129,135.80 |
DisclosureSEC source: 0001193805-17-001299 · e616385_4-jgrossman.xml · nonDerivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:02 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 118,861 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001193805-17-001057 · e616264_4-jgrossman.xml · derivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,861 Underlying: Common Stock · 118,861 shares Expires 2027-06-06 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) June 6, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 01:12 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001193805-17-000277 · e615797_4-jgrossman.xml · derivative · entry 1 Grossman Jerrold B · CIK 0001542519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-02-14 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) February 14, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.